Phio Pharmaceuticals (NASDAQ:PHIO) versus Unicycive Therapeutics (NASDAQ:UNCY) Head-To-Head Review

Phio Pharmaceuticals (NASDAQ:PHIO) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Profitability

This table compares Phio Pharmaceuticals and Unicycive Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Risk & Volatility

Phio Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500.

Valuation & Earnings

This table compares Phio Pharmaceuticals and Unicycive Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70 million	($1.38)	-0.73
Unicycive Therapeutics	$680,000.00	198.98	-$26.56 million	($2.21)	-2.24

Phio Pharmaceuticals has higher earnings, but lower revenue than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Phio Pharmaceuticals and Unicycive Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1	0	1	0	2.00
Unicycive Therapeutics	2	0	5	0	2.43

Phio Pharmaceuticals currently has a consensus price target of $14.00, indicating a potential upside of 1,286.14%. Unicycive Therapeutics has a consensus price target of $21.75, indicating a potential upside of 340.28%. Given Phio Pharmaceuticals’ higher possible upside, equities research analysts clearly believe Phio Pharmaceuticals is more favorable than Unicycive Therapeutics.

Summary

Phio Pharmaceuticals beats Unicycive Therapeutics on 7 of the 12 factors compared between the two stocks.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.